Abstract

BackgroundRadial Diffusivity (RD) has been suggested as a promising biomarker associated with the level of myelination in MS lesions. However, the level of RD within the lesion is affected not only by loss of myelin sheaths, but also by the degree of tissue destruction. This may lead to exaggeration of diffusivity measures, potentially masking the effect of remyelination.ObjectiveTo test the hypothesis that the T2 hyperintense lesion edge that extends beyond the T1 hypointense lesion core is less affected by tissue loss, and therefore a more appropriate target for imaging biomarker development targeting de- and re-myelination.MethodPre- and post-gadolinium (Gd) enhanced T1, T2 and DTI images were acquired from 75 consecutive RRMS patients. The optic radiation (OR) was identified in individual patients using a template-based method. T2 lesions were segmented into T1-hypointense and T1-isointense areas and lesion masks intersected with the OR. Average Radial, Axial and Mean diffusivity (RD, AD and MD) and fractional anisotropy (FA) were calculated for lesions of the entire brain and the OR. In addition, Gd enhancing lesions were excluded from the analysis.Results86% of chronic T2 lesions demonstrated hypointense areas on T1-weighted images, which typically occupied the central part of each T2 lesion, taking about 40% of lesional volume. The T1-isointense component of the T2 lesion was most commonly seen as a peripheral ring of relatively constant thickness (“T2-rim”). While changes of diffusivity between adjacent normal appearing white matter and the “T2-rim” demonstrated a disproportionally high elevation of RD compare to AD, the increase of water diffusion was largely isointense between the “T2-rim” and T1-hypointense parts of the lesion.ConclusionDistinct patterns of diffusivity within the central and peripheral components of MS lesions suggest that axonal loss dominates in the T1 hypointense core. The effects of de/remyelination may be more readily detected in the “T2-rim”, where there is relative preservation of structural integrity. Identifying and separating those patterns has an important implication for clinical trials of both neuroprotective and, in particular, remyelinating agents.

Highlights

  • Recent interest in the development of remyelinating therapies has increased demand for reliable in vivo surrogate markers of remyelination

  • In the current study we examined the directional diffusivity in optic radiation (OR) lesions of Relapsing-Remitting MS (RRMS) patients

  • Application of novel compartmentalized approach suggested new way of assessing lesional diffusivity which may facilitate the measurement of demyelination/remyelination in deep brain lesions and potentially serve as an outcome measure in therapeutic trials of emerging pro-reparative treatment

Read more

Summary

Introduction

Recent interest in the development of remyelinating therapies has increased demand for reliable in vivo surrogate markers of remyelination. Quantification of the diffusion characteristics of brain tissue, in particular Radial Diffusivity, has been suggested as a promising imaging biomarker associated with the level of tissue myelination. Some recent studies have failed to demonstrate an unequivocal relationship between increased RD and the degree of demyelination, suggesting that this measure is not pathologically specific (Klawiter et al, 2012). Radial Diffusivity (RD) has been suggested as a promising biomarker associated with the level of myelination in MS lesions. The level of RD within the lesion is affected by loss of myelin sheaths, and by the degree of tissue destruction. This may lead to exaggeration of diffusivity measures, potentially masking the effect of remyelination. Identifying and separating those patterns has an important implication for clinical trials of both neuroprotective and, in particular, remyelinating agents

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call